HIV New Product Introduction Toolkit

The Transitioning children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) Study was conducted in Benin, Nigeria, and Uganda....

In mid-2021, national HIV programmes began to transition treatment for children living with HIV to dolutegravir (DTG) 10 ...

CHAI developed these frequently asked questions (FAQs) to lay out information for communities and PLHIV on the subject of DRV/r (400/50...

CHAI has developed a generic training curriculum that is intended to be adapted for local contexts and their respective training plans.

Darunavir (DRV) is a best-in-class protease inhibitor (PI) used in combination with other antiretroviral (ARV) drugs for the...

CHAI is pleased to share a customizable guide to assist healthcare workers with prescribing and dispensing second-line (2L) DRV/r...

A presentation with the latest information on DRV/r (400/50mg) and considerations for adult second line treatment optimization.

CHAI developed these frequently asked questions (FAQs) to lay out information for national HIV programs considering the adoption and...

CHAI has developed new resources to support healthcare worker decision-making and counselling around pDTG. pDTG HCW Worker Overview Video...

CHAI has developed this memo to lay out information for national HIV programs considering the introduction of pediatric...

This policy brief outlines key considerations to facilitate effective transition to more clinically appropriate regimens as optimal...

Optimal and FASTER CAB members, with technical support from CHAI, developed a multi-media package of treatment literacy and advocacy...

This sixth edition of the Optimal Formulary and Limited-use List supports the transition to optimal WHO-recommended ART regimens for...

A CHAI-curated repository of clinical studies in the development and implementation of pediatric DTG.